Autonomous Drone Helps Save the Life of a Cardiac Arrest Patient

Everdrone's Emergency Medical Aerial Delivery service (EMADE), an innovative link in the chain of life-saving measures of Region Västra Götaland, Sweden, was put to the toughest of tests in the morning of December the 9th of 2021

Everdrone’s Emergency Medical Aerial Delivery service (EMADE), an innovative link in the chain of life-saving measures of Region Västra Götaland, Sweden, was put to the toughest of tests in the morning of December the 9th of 2021. In the Swedish city of Trollhättan, a 71-year-old man was shoveling snow in his driveway when he suffered an out-of-hospital cardiac arrest (OHCA).

Thanks to the combination of an immediate emergency call, the quick actions of Dr. Mustafa Ali and the swift delivery of an Automated External Defibrillator (AED), lifesaving measures through defibrillation could be initiated before the arrival of the ambulance, and his life was saved. The time from the alarm until the AED was safely delivered at the doorstep of the incident address was just over three minutes. After the initial treatment on site, the patient was rushed to the hospital and is today fully recovered.

“I can’t put into words how thankful I am to this new technology and the speedy delivery of the defibrillator. If it wasn’t for the drone I probably wouldn’t be here,” says the 71-year-old patient who has made a full recovery and now has been able to return to his home.

For Dr. Mustafa Ali the experience was just as gratifying, despite the gravity of the situation.

“I was on my way to work at the local hospital when I looked out the car window and saw a man collapsed in his driveway,” says Dr. Ali. “I immediately understood that something was wrong and rushed to help. The man had no pulse, so I started doing CPR (cardiopulmonary resuscitation) while asking another bystander to call 112 (the Swedish emergency number). Just minutes later, I saw something flying above my head. It was a drone with a defibrillator!”

Thanks to Dr. Ali, and the use of the defibrillator, life-saving treatment was initiated early and, which in the end, meant that the life of the patient was saved.

“This is a truly revolutionary technology that needs to be implemented all over; sudden cardiac arrests can happen to anyone, not just old people with arteriosclerosis” says the patient.

The drone delivery system in Region Västra Götaland is developed and operated by Everdrone, a world-leading company in autonomous drone solutions. The solution has been developed and is continuously improved in close collaboration with Center for Resuscitation Science at Karolinska Institutet, SOS Alarm and Region Västra Götaland. The operations are also supported by Vinnova, Swelife and Medtech4Health.

“This is an excellent real-world example of how Everdrone’s cutting-edge drone technology, fully integrated with emergency dispatch, can minimize the time for access to life-saving AED equipment,” says Mats Sällström, CEO of Everdrone.

Approximately 275,000 patients in Europe and 350,000 in the US, suffer from OHCA annually. Approximately 70% of OHCAs occur in private homes without AEDs on site, and ambulance response times are often too long to save the life of the patient. The chance of survival decreases by 7–10% with each minute following the collapse, and consequently, the current survival rate among OHCA patients is merely 10%. Everdrone’s innovative airborne AED delivery service is a proven method to tackle this critical issue. The service can currently reach 200,000 residents in Sweden and is expected to expand to more locations in Europe during 2022.

The drone system has been scientifically established to cut response times and the full study is published in the European Heart Journal.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy